US 11,904,145 B2
Diabetes therapy management systems, methods, and devices
John Sjolund, Los Altos, CA (US); Ambika Srinath, San Francisco, CA (US); Andrew Bochenko, Redwood City, CA (US); George Crothall, Oceanside, CA (US); Bryan Mazlish, Palo Alto, CA (US); Lane Desborough, Thousand Oaks, CA (US); Jennifer Martin Block, Menlo Park, CA (US); Sarah Matarese, San Jose, CA (US); and Linda Mackowiak, Cazenovia, NY (US)
Assigned to Bigfoot Biomedical, Inc., Milpitas, CA (US)
Filed by Bigfoot Biomedical, Inc., Milpitas, CA (US)
Filed on Oct. 26, 2021, as Appl. No. 17/452,319.
Application 17/452,319 is a continuation of application No. 16/218,056, filed on Dec. 12, 2018, granted, now 11,154,660.
Claims priority of provisional application 62/682,872, filed on Jun. 9, 2018.
Claims priority of provisional application 62/628,808, filed on Feb. 9, 2018.
Claims priority of provisional application 62/597,868, filed on Dec. 12, 2017.
Claims priority of provisional application 62/597,809, filed on Dec. 12, 2017.
Prior Publication US 2022/0040414 A1, Feb. 10, 2022
Int. Cl. A61B 5/00 (2006.01); A61M 5/315 (2006.01); G16H 20/17 (2018.01); A61B 5/145 (2006.01); A61M 5/20 (2006.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 40/63 (2018.01); G16H 20/60 (2018.01); A61M 5/168 (2006.01); G16H 40/67 (2018.01); G16H 20/13 (2018.01); A61K 38/28 (2006.01); A61M 5/32 (2006.01); A61M 5/00 (2006.01); A61M 5/142 (2006.01); A61M 5/24 (2006.01); A61M 5/31 (2006.01)
CPC A61M 5/31546 (2013.01) [A61B 5/0004 (2013.01); A61B 5/14532 (2013.01); A61B 5/4836 (2013.01); A61B 5/4839 (2013.01); A61B 5/7405 (2013.01); A61B 5/746 (2013.01); A61B 5/7435 (2013.01); A61B 5/7455 (2013.01); A61K 38/28 (2013.01); A61M 5/003 (2013.01); A61M 5/168 (2013.01); A61M 5/20 (2013.01); A61M 5/31525 (2013.01); A61M 5/3202 (2013.01); G16H 20/13 (2018.01); G16H 20/17 (2018.01); G16H 20/60 (2018.01); G16H 40/63 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); A61B 5/14546 (2013.01); A61B 5/681 (2013.01); A61M 5/24 (2013.01); A61M 2005/14208 (2013.01); A61M 2005/2006 (2013.01); A61M 2005/3125 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3306 (2013.01); A61M 2205/3561 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/502 (2013.01); A61M 2205/505 (2013.01); A61M 2205/581 (2013.01); A61M 2205/582 (2013.01); A61M 2205/583 (2013.01); A61M 2209/06 (2013.01); A61M 2230/201 (2013.01)] 70 Claims
OG exemplary drawing
 
1. A diabetes management system, comprising:
an insulin delivery device, comprising:
a cap detector for detecting at least one of a capping event where a cap is secured over the insulin delivery device or an uncapping event where the cap is at least partially removed from over insulin delivery device; and
a dosing event detector for detecting at least one dosing event of the insulin delivery device;
a transmitter for transmitting dosing data related to the detected at least one dosing event, the dosing data comprising one or more of time of dose, duration of dose, or amount of dose;
a remote device in wireless communication with the insulin delivery device, the remote device comprising:
a receiver for receiving the dosing data; and
a display for displaying the dosing data and dosing recommendations within a graphical user interface of the remote device.